| Yesterday | ||||
JPMorgan, Goldman Sachs,… JPMorgan, Goldman Sachs, BofA, Cowen, Guggenheim and William Blair are acting as joint book running managers for the offering. | ||||
| Tuesday | ||||
J.P. Morgan, Goldman… J.P. Morgan, Goldman Sachs & Co. and BofA Securities are acting as joint lead book-running managers for the offering. Cowen, Guggenheim Securities and William Blair are acting as book-running managers for the offering. BTIG is acting as co-manager for the offering. | ||||
Preliminary and unaudited… Preliminary and unaudited revenue for full year 2019 is expected to be in the range of $84 - $85 million, reflecting growth of approximately 52% at the midpoint of the range over full year 2018. "We are pleased with our strong performance in the fourth quarter, as we continued accelerating our efforts to scale our business to aggressively pursue the large pipeline opportunity in front of us," said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. "Following our FDA clearance and reimbursement progress for clonoSEQ, we focused on investing in market development activities to educate clinicians about the benefits of monitoring MRD for their patients, activating key accounts, and establishing order workflow. During the fourth quarter, these investments translated into meaningful growth in our clinical volumes which grew by more than 25% from third quarter 2019." Partly reflecting these investments, Adaptive expects operating and net loss for the year ended December 31, 2019 to increase compared to 2018 and expects operating and net loss for the three months ended December 31, 2019 to increase compared to the three months ended September 30, 2019. | ||||
| Over a week ago | ||||
Adaptive Biotechnologies… Adaptive Biotechnologies Corporation (ADPT) announced a multi-year, global diagnostic agreement with Genentech, a member of the Roche Group (RHHBY) to utilize Adaptive's next-generation sequencing-based clonoSEQ Assay to assess minimal residual disease status in response to venetoclax in the registrational Phase III CRISTALLO study for the treatment of newly diagnosed people with chronic lymphocytic leukemia plus additional future venetoclax studies in CLL. Adaptive and Genentech will partner to incorporate the clonoSEQ Assay to measure MRD status as a primary endpoint in this registrational study. Under the terms of the agreement, Adaptive will receive upfront and sample testing payments to advance the development and potential expedited approval of venetoclax in this setting. Venetoclax is a first-in class small molecule selective B-cell lymphoma-2 inhibitor being studied in investigational trials for the treatment of people with previously untreated CLL or small lymphocytic lymphoma. Adaptive and Genentech will evaluate the depth and duration of response to venetoclax and obinutuzumab by using Adaptive's clonoSEQ Assay as a primary endpoint to measure and monitor MRD negativity from peripheral blood in newly diagnosed CLL. clonoSEQ is the only MRD test authorized by the U.S. Food and Drug Administration to detect and monitor MRD in multiple myeloma and B-Cell acute lymphoblastic leukemia using DNA from bone marrow samples. clonoSEQ is available as a laboratory develop test in CLL using DNA from peripheral blood and bone marrow. MRD is a measure of the amount of cancer in the body, specifically the very small number of cancer cells that remain during or after treatment. MRD testing can be useful to see if a patient is responding to treatment or if the cancer has come back | ||||
JPMorgan analyst Tycho… JPMorgan analyst Tycho Peterson expects organic growth in the Life Science Tools & Diagnostics space to mirror 2019 against a "healthy backdrop" across biopharma and academic end markets. His top picks for 2020 are Danaher (DHR) and Thermo Fisher (TMO). The analyst also urges investors to take advantage of any downturn to add to "open-ended growth stories that trade at premium valuations," with Intuitive Surgical (ISRG) his top pick in this category. On the Smid-cap side, Peterson favors Guardant Health (GH), 10x Genomics (TXG) and NanoString (NSTG). For investors with a longer-term horizon, he recommend Adaptive Biotechnologies (ADPT). The analyst also continues to recommend Avantor (AVTR). | |
Adaptive Biotechnologies… Adaptive Biotechnologies announced that Palmetto GBA, a Medicare Administrative Contractor that assesses diagnostic technologies through its MolDX program, has expanded coverage of the clonoSEQ Assay to include monitoring minimal residual disease in Medicare patients with chronic lymphocytic leukemia. This adds to existing Medicare coverage in B-cell acute lymphoblastic leukemia and multiple myeloma, which was established in January 2019. Medicare coverage for clonoSEQ is aligned with clinical practice guidelines in covered disease states which support assessing MRD at multiple time points throughout therapy to monitor treatment response and help predict patient outcomes. This expanded coverage policy is effective immediately and continues the positive momentum for clonoSEQ with over 175M lives covered to date. |
| Over a month ago | ||||
Meeting to be held in New… Meeting to be held in New York on December 12 hosted by JPMorgan. | ||||
Meeting to be held in New… Meeting to be held in New York on December 12 hosted by JPMorgan. | ||||
Adaptive Biotechnologies… Adaptive Biotechnologies (ADPT) announced a multi-year, global collaboration agreement with AbbVie (ABBV) to utilize Adaptive's next-generation sequencing, or NGS,-based clonoSEQ Assay to assess minimal residual disease, or MRD, status in response to venetoclax across multiple myeloma, or MM, clinical trials. "Adaptive is thrilled to partner with AbbVie to support the clinical development and potential regulatory approval of venetoclax in multiple myeloma," said Chad Robins, CEO and co-founder of Adaptive Biotechnologies. "This partnership supports the growing use of clonoSEQ in drug development as an accurate, reliable method to assess response to new treatments that can meaningfully improve patient care." | ||||